Last reviewed · How we verify
NCT05367895
Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose
trial testing COVID-19 Vaccine (Vero Cell), Inactivated in COVID-19 in 14,000 participants. Status unknown.
15 August 2022
Quick facts
| Lead sponsor | Sinovac Research and Development Co., Ltd. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 14,000 |
| Start date | 30 July 2022 |
| Primary completion | 15 August 2022 |
| Estimated completion | 15 February 2023 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- COVID-19 Vaccine (Vero Cell), Inactivated — full drug profile →
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Sinovac Research and Development Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a retrospective test-negative case-control study of COVID-19 Vaccine (CoronaVac®) manufactured by Sinovac Research and Development Co., Ltd.The main purpose of this study is to measure vaccine effectiveness of homologous booster-dose vaccination with CoronaVac® against laboratory-confirmed symptomatic disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05367895
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of COVID-19 Vaccine (Vero Cell), Inactivated
Trials testing the same drug.
- NCT05433272 — Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated · Phase 3 · unknown
- NCT06381843 — A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster · NA · completed
- NCT05463354 — Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster · Phase 2 · completed
- NCT05323435 — Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV) · Phase 2 · completed
- NCT05382871 — Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years an · Phase 3 · unknown
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Sinovac Research and Development Co., Ltd. trials
Trials by the same sponsor.
- NCT06183216 — A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine · Phase 1 · completed
- NCT05156632 — Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above · Phase 3 · withdrawn
- NCT05165732 — Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manu · Phase 4 · suspended
- NCT05150496 — Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccin · Phase 2 · suspended
- NCT05381350 — Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Heal · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05367895 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sinovac Research and Development Co., Ltd.
- Last refreshed: 12 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05367895.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing